Article

Using suprachoroidal drug delivery

Local delivery of pharmacotherapy to the eye has long been used for anterior segment disease, but various routes for delivery have also been investigated, said Timothy Olsen, MD.

Orlando-Local delivery of pharmacotherapy to the eye has long been used for anterior segment disease, but various routes for delivery have also been investigated, said Timothy Olsen, MD.

Intravitreal injections represent the current standard of care for treating retinal disorders, but the injection systems are very inexpensive, running about $0.15 for the syringe. Yet, the diffusion of drug from the vitreous means most agents have a relatively short half-life.

“The suprachoroidal space is the next logical space after the sclera to investigate,” said Dr. Olsen, Emory University, Atlanta.

Bigger molecules will move slowly across the sclera, and smaller ones will move much quicker. He described the cannulation of the suprachoroidal space using a flexible catheter for sustained delivery to the choroid and retina that involves first creating the sclerectomy at the suprachoroidal space.

“We then have the cannula loaded with Healon and triamcinolone" and pass the catheter into the sclera, Dr. Olsen added. “We can deliver drugs through the suprachoroidal to the nerves.”

 

Biologics in the suprachoroidal space, he noted, have been demonstrated to have a dramatically shorter half-life. Optimizing the formulation of the small molecule or biologic may improve sustained delivery in the suprachoroidal space, and could represent a unique avenue for better drug delivery.

“Cellular delivery is a real possibility and has great potential,” Dr. Olsen said.

 

For more articles in this issue of Ophthalmology Times’ Conference Brief, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.